London, England, United Kingdom In 2010 was created Enso Ventures, which is appeared as VC. The fund was located in Europe if to be more exact in United Kingdom. The main department of described VC is located in the London.
The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2017. The higher amount of exits for fund were in 2019. Speaking about the real fund results, this VC is 7 percentage points less often commits exit comparing to other organizations. The typical startup value when the investment from Enso Ventures is 5-10 millions dollars. Opposing the other organizations, this Enso Ventures works on 2 percentage points less the average amount of lead investments. The common things for fund are deals in the range of 5 - 10 millions dollars.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Enso Ventures, startups are often financed by The FSE Group, Novartis Venture Fund, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are Novartis Venture Fund, Flagship Pioneering, The FSE Group. In the next rounds fund is usually obtained by Flagship Pioneering, Oxford Capital Partners, Octopus Ventures.
We also calculated 2 valuable employees in our database.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Oil and Gas, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Cellectar Biosciences, NeuroVia, Seres Health.
Related Funds
Funds with similar focus
| Fund Name | Location |
| 301 Ventures | College Park, Maryland, United States |
| Anlaiye | China, Shanghai |
| Apricot Capital | Boston, Massachusetts, United States |
| Banque Populaire Rives de Paris | France, Ile-de-France, Paris |
| Beijing Qingda Huachuang Investment Management | Beijing, Beijing, China |
| Comtech Systems | Port Angeles, United States, Washington |
| FTX Exchange | Berkeley, California, United States |
| INCUBATE | Australia, New South Wales, Sydney |
| Kalamazoo | - |
| Lightspeed India Partners | Delhi, India, New Delhi |
| LUBio Science | - |
| PinYi Capital | - |
| Rheinland Venture Capital | Aachen, Germany, Nordrhein-Westfalen |
| Sarum Partners | Abergavenny, Monmouthshire, United Kingdom |
| Serco | Reston, United States, Virginia |
| ShawSpring Partners | Boston, Massachusetts, United States |
| Sweat Equities | Dallas, Texas, United States |
| TMS Entertainment | - |
| UNDP | New York, New York, United States |
| Yujiangxian Ganghong Touzi | China, Jiangxi, Yingtan |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cognitive Geology | $2M | 06 Oct 2017 | Scotland | ||
NeuroVia | $14M | 20 Jul 2017 | San Francisco, California, United States | ||
Cavion | $26M | 06 Jan 2017 | Virginia, United States | ||
Galera Therapeutics | $5M | 03 Feb 2016 | Pennsylvania, United States | ||
Seres Therapeutics | $10M | 23 May 2014 | Cambridge, Massachusetts, United States | ||
Axcella | 11 Dec 2013 | Cambridge, Massachusetts, United States | |||
Seres Therapeutics | $10M | 21 Nov 2013 | Cambridge, Massachusetts, United States | ||
Egalet | $14M | 07 May 2012 | Radnor Township, Pennsylvania, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cognitive Geology | $2M | 06 Oct 2017 | Scotland | ||
NeuroVia | $14M | 20 Jul 2017 | San Francisco, California, United States | ||
Cavion | $26M | 06 Jan 2017 | Virginia, United States | ||
Galera Therapeutics | $5M | 03 Feb 2016 | Pennsylvania, United States | ||
Seres Therapeutics | $10M | 23 May 2014 | Cambridge, Massachusetts, United States | ||
Axcella | 11 Dec 2013 | Cambridge, Massachusetts, United States | |||
Seres Therapeutics | $10M | 21 Nov 2013 | Cambridge, Massachusetts, United States | ||
Egalet | $14M | 07 May 2012 | Radnor Township, Pennsylvania, United States |
